'Seclidemstat also has the potential for treating various other cancer types. For instance, MD Anderson recently announced an investigator initiated trial studying seclidemstat in hematological cancers. In addition, Salarius hopes to study seclidemstat in other solid tumors in combination with immunotherapy or other targeted anti-cancer agents. And, with $33 million in cash as of June 30, 2021, it not only has the expertise but the financial ability to fund its clinical trials — and build a pipeline supporting company growth — for the future'.
$SLRX is looking to change the treatment paradigm by developing a less cytotoxic cancer treatment that is given as an oral tablet. Salarius’ treatment should not have the harsh side effects associated with chemotherapy, including hair loss and long-term nerve damage.
https://www.benzinga.com/general/biotech/21/10/23412584/could-the-future-hold-a-less-toxic-cancer-treatment-in-the-form-of-a-tablet?utm_campaign=partner_feed&utm_source=TechInvestorNews&utm_medium=partner_feed&utm_content=site
Recent SLRX News
- Form 8-K - Current report • Edgar (US Regulatory) • 08/15/2024 08:04:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 08:09:41 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2024 09:10:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/25/2024 09:03:14 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/25/2024 09:01:35 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/22/2024 09:25:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/19/2024 09:13:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/11/2024 12:15:44 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 06/17/2024 12:11:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/17/2024 12:05:28 PM
- Clinical Data on Salarius Pharmaceuticals’ Seclidemstat in Patients with MDS and CMML Presented at the 2024 European Hematology Association Annual Meeting • GlobeNewswire Inc. • 06/17/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/14/2024 08:04:58 PM
- Salarius Pharmaceuticals Announces 1-for-8 Reverse Stock Split • GlobeNewswire Inc. • 06/12/2024 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/13/2024 08:17:10 PM
- Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 03/22/2024 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 09:02:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/22/2024 09:29:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/22/2024 09:25:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/22/2024 09:13:07 PM
- Salarius Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing Expenses • GlobeNewswire Inc. • 02/22/2024 01:00:00 PM
- Salarius Pharmaceuticals Issued U.S. Patent for Next-Generation Targeted Protein Degraders • GlobeNewswire Inc. • 01/16/2024 01:00:00 PM
- Investigator-initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals’ Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Resumes Patient Enrollment • GlobeNewswire Inc. • 01/03/2024 01:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 10:04:46 PM
- Salarius Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development Program • GlobeNewswire Inc. • 11/07/2023 01:30:00 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM